Compare DOO & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOO | CRNX |
|---|---|---|
| Founded | 1937 | 2008 |
| Country | Canada | United States |
| Employees | 17000 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | N/A | 2018 |
| Metric | DOO | CRNX |
|---|---|---|
| Price | $61.36 | $83.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $85.67 | $76.75 |
| AVG Volume (30 Days) | 179.1K | ★ 7.0M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $8.48 | $720.10 |
| Revenue Next Year | $5.10 | $184.67 |
| P/E Ratio | $338.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.83 | $25.83 |
| 52 Week High | $81.89 | $84.00 |
| Indicator | DOO | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 92.12 |
| Support Level | $60.02 | $43.40 |
| Resistance Level | $63.73 | N/A |
| Average True Range (ATR) | 1.46 | 0.19 |
| MACD | 0.13 | -0.48 |
| Stochastic Oscillator | 96.98 | 75.00 |
BRP designs, develops, manufactures, distributes, and markets snowmobiles, all-terrain vehicles, and personal watercraft under the Ski-Doo, Sea-Doo, Can-Am, and Lynx brand names. It also builds engines under the Rotax brand (after shuttering the Evinrude outboard engine business in 2020) and offers clothing, parts, and accessories that cater to its core consumers. In 2018, BRP created a marine group, which has largely been divested; Manitou was sold in the third quarter of fiscal 2026, and Telwater remains up for sale. At the end of fiscal 2026, the company sold its products through a network of more than 2,050 independent dealers and 140 distributors in around 110 countries.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.